Embecta (NASDAQ:EMBC) Posts Quarterly Earnings Results, Misses Expectations By $0.15 EPS
by Amy Steele · The Cerbat GemEmbecta (NASDAQ:EMBC – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.15), FiscalAI reports. The company had revenue of $221.80 million during the quarter, compared to analyst estimates of $235.67 million. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. Embecta’s revenue for the quarter was down 14.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.70 EPS. Embecta updated its FY 2026 guidance to 1.550-1.75 EPS.
Here are the key takeaways from Embecta’s conference call:
- The quarter missed expectations with Q2 revenue of approximately $222 million (down 14.4% y/y) and full‑year fiscal 2026 revenue guidance cut to $1.015B–$1.035B (organic midpoint ~ $995M), with ~70% of the ~$75M guidance reduction driven by pen needles and much of the share loss concentrated at a single large U.S. customer.
- Profitability and cash outlook were materially revised — adjusted operating margin guidance lowered to 22.25%–23.25%, adjusted EPS to $1.55–$1.75 (from $2.80–$3.00), and free cash flow guidance cut to $95M–$105M (from $180M–$200M), with a higher adjusted tax rate and near‑term dilution from the pending acquisition contributing to the change.
- Embecta expects to close the Owen Mumford acquisition this month (upfront ~GBP100M, up to GBP50M earnouts), which adds the Aidaptus auto‑injector platform and should diversify the portfolio beyond insulin devices, contribute ~$30M in FY26 (4 months) and be accretive over time.
- Strategic execution on GLP‑1 and product portfolio progress continues — ~40% of identified GLP‑1 partners are in active negotiations or contracts, several partners launched co‑packed generics in India, and new market‑appropriate pen needles/syringes are advancing through regulatory submissions and selective commercial launches.
- Capital allocation was reshaped — the board authorized up to $100M in share repurchases, cut the quarterly dividend to $0.01 from $0.15, plans ~$150M of debt repayment in 2026, and has initiated a cost‑structure/organizational review to address the guidance shortfall.
Embecta Trading Down 53.9%
EMBC stock traded down $4.98 during midday trading on Tuesday, hitting $4.27. 7,400,960 shares of the company’s stock were exchanged, compared to its average volume of 869,560. Embecta has a 1-year low of $4.02 and a 1-year high of $15.55. The business has a 50-day simple moving average of $9.26 and a two-hundred day simple moving average of $11.27. The stock has a market capitalization of $252.69 million, a PE ratio of 1.80 and a beta of 1.09.
Wall Street Analysts Forecast Growth
EMBC has been the subject of several recent analyst reports. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, January 21st. Mizuho cut their target price on Embecta from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Monday, April 13th. Finally, BTIG Research reissued a “buy” rating and set a $25.00 target price on shares of Embecta in a research note on Friday, February 6th. One analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $18.50.
View Our Latest Research Report on Embecta
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of EMBC. Royal Bank of Canada boosted its position in shares of Embecta by 38.3% during the first quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock worth $232,000 after buying an additional 5,036 shares during the period. AQR Capital Management LLC boosted its position in shares of Embecta by 3.7% during the first quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock worth $2,738,000 after buying an additional 8,109 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Embecta by 2.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after buying an additional 1,159 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Embecta by 4.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock worth $2,195,000 after buying an additional 7,894 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of Embecta by 224.0% during the first quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after buying an additional 91,729 shares during the period. 93.83% of the stock is currently owned by hedge funds and other institutional investors.
About Embecta
Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.